HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Esperion Therapeutics, Inc. +1.43% Pre
Esperion Therapeutics, Inc. ESPR | 2.13 2.16 | +1.43% +1.41% Pre |
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:
ESPR) with a Buy and maintains $16 price target.